CIRCIO HOLDING ASA: INFORMATION ABOUT WARRANTS AND COMMENCEMENT OF TRADING

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 16 February 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 12 February 2026 regarding the registration of share capital increases in connection with the rights issue raising gross proceeds of NOK 50 million (the "Rights Issue") and in connection with the private placement of 15,018,945 new shares (the "Private Placement").

A total of 67,680,945 warrants (the "Warrants") have been issued on ISIN NO 0013711523 in connection with the Rights Issue (including the warrants issued as commission to the pre-subscribers in the Rights Issue) and the Private Placement. The Warrants will be listed and tradable on the Oslo Stock Exchange under the ticker code "CRNAS". The trading period for the Warrants commences today, 16 February 2026, and will end four trading days prior to 9 June 2026 at 16.30 hours (CEST).

Each Warrant will give the holder the right to subscribe for and be allocated one (1) new share in the Company at an exercise price equal to 80% of the volume-weighted average price of the Company's shares on the Oslo Stock Exchange in the period between 8 May 2026 to 22 May 2026, but not less than the nominal value of Company's shares at the time of the Exercise Period (as defined below).

The Warrants may be exercised in the period from 08:00 hours (CEST) on 26 May 2026 to 16:30 hours (CEST) on 9 June 2026 (the "Exercise Period"). Additional information regarding the exercise of the Warrants will be provided closer to the Exercise Period.

Any Warrants not exercised within 16:30 hours (CEST) on 9 June 2026 will have no value and will lapse without compensation to the holder.

Selling and Transfer Restrictions: The grant or purchase of Warrants by persons resident in, or who are citizens of countries other than Norway or Sweden, may be affected by the laws of the relevant jurisdiction. For a further description of such restrictions, reference is made to the Section 11 "Selling and Transfer Restrictions" in the securities note dated 13 January 2026 (the "Securities Note", and together with a registration document dated 1 October 2025, and a registration document supplement and summary dated 13 January 2026, comprise the "Prospectus"). Holders of Warrants who do not exercise Warrants to subscribe for new shares in the Company may experience a dilution of their shareholding in the Company. For a further description of such dilutive effect, reference is made to Section 5.20 "Dilution" in the Securities Note.

For more information pertaining to the Warrants, please refer to the Prospectus. The Prospectus is available on the Company's website: https://www.circio.com/en/rightsissue2026/.

This information is subject to the disclosure requirements pursuant to the Continuing Obligations and Section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com

Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com

About Circio Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.